Substance P Drives Cancer Progression in Head and Neck Tumors via NK1 Receptor
The neuropeptide substance P promotes head and neck cancer progression through NK1 receptor activation, driving cell proliferation, migration, and chronic inflammation that transitions to neoplastic transformation.
Quick Facts
What This Study Found
Substance P and NK1R upregulate cell proliferation, cell migration, and chronic inflammation in head and neck cancers, playing a role in the transition from chronic mucosal inflammation to neoplastic transformation and progression.
Key Numbers
~1.5 million new cases/year; ~500,000 deaths/year; SP/NK1R upregulates proliferation, migration, inflammation; relevant to laryngeal and oral squamous cell carcinomas
How They Did This
Narrative review of published literature on the substance P/NK1R system in chronic inflammation and carcinogenesis of the head and neck region.
Why This Research Matters
If substance P drives the inflammatory-to-cancer transition in the head and neck, NK1R antagonists (substance P blockers) could potentially prevent or treat these cancers — a completely new therapeutic approach.
The Bigger Picture
The role of neuropeptides in cancer is increasingly recognized. Substance P's involvement in inflammation-to-cancer transitions suggests that the nervous system plays a more active role in tumor development than previously understood, opening new avenues for cancer prevention.
What This Study Doesn't Tell Us
Narrative review with no new experimental data. Direct causal evidence for SP driving cancer in humans is limited. NK1R antagonists have not been tested as anticancer agents in head and neck cancer clinical trials.
Questions This Raises
- ?Could NK1R antagonists prevent head and neck cancer in people with chronic oral/laryngeal inflammation?
- ?Is substance P a viable biomarker for identifying patients at risk of malignant transformation?
- ?Would combining NK1R blockers with standard cancer treatments improve outcomes?
Trust & Context
- Key Stat:
- 1.5M cases/year Head and neck cancer is a major global health burden, and substance P/NK1R may drive the inflammatory transition to malignancy in these tissues
- Evidence Grade:
- Not applicable (narrative review). Based on a combination of in vitro, animal, and clinical observational data.
- Study Age:
- Published in 2021. Research on NK1R antagonists as potential anticancer agents continues.
- Original Title:
- Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.
- Published In:
- International journal of environmental research and public health, 19(1) (2021)
- Authors:
- Esteban, Francisco(3), Ramos-García, Pablo, Muñoz, Miguel(5), González-Moles, Miguel Ángel
- Database ID:
- RPEP-05369
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How does substance P promote cancer?
Substance P activates the NK1 receptor, which triggers cell multiplication, helps cancer cells migrate, and sustains chronic inflammation. In the mouth and throat, this can drive the transition from chronic inflammation to precancerous and cancerous changes.
Could blocking substance P prevent head and neck cancer?
Theoretically, NK1R antagonists could interrupt the inflammation-to-cancer transition. Drugs that block NK1R already exist for other conditions (like nausea), but they haven't been tested as cancer prevention agents in clinical trials yet.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05369APA
Esteban, Francisco; Ramos-García, Pablo; Muñoz, Miguel; González-Moles, Miguel Ángel. (2021). Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.. International journal of environmental research and public health, 19(1). https://doi.org/10.3390/ijerph19010375
MLA
Esteban, Francisco, et al. "Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.." International journal of environmental research and public health, 2021. https://doi.org/10.3390/ijerph19010375
RethinkPeptides
RethinkPeptides Research Database. "Substance P and Neurokinin 1 Receptor in Chronic Inflammatio..." RPEP-05369. Retrieved from https://rethinkpeptides.com/research/esteban-2021-substance-p-and-neurokinin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.